Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

Publication | Closed Access

DOI

249

Citations

References

2020

Year

François Venter, Simiso Sokhela, Bryony Simmons, Michelle Moorhouse, Lee Fairlie, Nkuli Mashabane, Celicia Serenata, Godspower Akpomiemie, Masebole Masenya, Ambar Qavi,

The Lancet HIV

Week 96Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirologyPharmacotherapyNon-inferiority TrialTenofovir AlafenamideHivAntiviral DrugMedicine